121.00

0.40% 0.48

After Hours: 121.00

Glaukos Corporation (GKOS)

Overview News Price History Option Chain Financials Discussions Forecast

Glaukos Corporation stock is traded at $121.00, with a volume of 491.64K. It is up +0.40% in the last 24 hours and up +24.72% over the past month. Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Previous Close:

$120.52

Open:

$121.02

24h Volume:

491.64K

Relative Volume:

0.62

Market Cap:

$7.03B

Revenue:

$507.44M

Net Income/Loss:

$-187.69M

P/E Ratio:

-36.99

EPS:

-3.271

Net Cash Flow:

$-39.06M

1W Performance:

+2.01%

1M Performance:

+24.72%

6M Performance:

+41.36%

1Y Performance:

+28.02%

1-Day Range:

$118.57

$122.00

1-Week Range:

$115.28

$122.00

52-Week Range:

$73.16

$130.23

Glaukos Corporation Stock (GKOS) Company Profile

Name

Glaukos Corporation

Sector

Healthcare (1112)

Industry

Medical Devices (143)

Phone

949-367-9600

Address

1 GLAUKOS WAY, ALISO VIEJO, CA

Employee

1,094

Twitter

@GlaukosCorp

Next Earnings Date

2024-11-04

Latest SEC Filings

GKOS's Discussions on Twitter

Compare GKOS vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GKOS Glaukos Corporation	121.00	7.00B	507.44M	-187.69M	-39.06M	-3.271
ABT Abbott Laboratories	101.56	175.59B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	341.24	132.47B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	87.10	113.14B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	64.61	94.85B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	78.20	45.09B	6.07B	1.06B	1.34B	1.8063

Glaukos Corporation Stock (GKOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-01-25	Initiated	Goldman	Buy
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-06-24	Initiated	UBS	Buy
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-24	Downgrade	Citigroup	Buy → Neutral
May-06-24	Upgrade	Jefferies	Hold → Buy
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight
Nov-28-23	Initiated	Truist	Buy
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-22-22	Initiated	Mizuho	Neutral
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight
Oct-04-22	Initiated	Needham	Buy
Jul-12-22	Upgrade	Stifel	Hold → Buy
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight
Jul-14-21	Downgrade	Oppenheimer	Outperform → Perform
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Apr-08-21	Upgrade	Oppenheimer	Perform → Outperform
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Upgrade	Citigroup	Sell → Neutral
Dec-09-20	Initiated	Oppenheimer	Perform
Nov-17-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Oct-08-20	Downgrade	JP Morgan	Neutral → Underweight
Jun-15-20	Initiated	Jefferies	Hold
Mar-05-20	Initiated	Citigroup	Sell
Feb-28-20	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-20	Upgrade	Berenberg	Hold → Buy
Dec-12-19	Downgrade	Wells Fargo	Outperform → Underperform
Sep-30-19	Downgrade	BofA/Merrill	Buy → Underperform
Mar-08-19	Initiated	BTIG Research	Neutral
Aug-30-18	Initiated	Berenberg	Hold
Aug-29-18	Upgrade	JP Morgan	Neutral → Overweight
Aug-03-18	Reiterated	Stifel	Hold
Jun-21-18	Downgrade	JP Morgan	Overweight → Neutral
Apr-13-18	Downgrade	Stifel	Buy → Hold
Mar-01-18	Reiterated	Cantor Fitzgerald	Buy
Mar-02-17	Reiterated	Cantor Fitzgerald	Overweight
Jan-06-17	Upgrade	Stifel	Hold → Buy
Oct-27-16	Initiated	Wells Fargo	Outperform

View All

Glaukos Corporation Stock (GKOS) Latest News

Apr 14, 2026

[Form 4] GLAUKOS Corp Insider Trading Activity - Stock Titan

Apr 14, 2026

Apr 13, 2026

Published on: 2026-04-14 04:05:55 - baoquankhu1.vn

Apr 13, 2026

Street Watch: What chart patterns are forming on Glaukos Corporation2026 Institutional & Weekly Return Optimization Plans - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Glaukos (NASDAQ: GKOS) affiliate sale reported in Form 144 - Stock Titan

Apr 10, 2026

(GKOS) Volatility Zones as Tactical Triggers - Stock Traders Daily

Apr 10, 2026

Apr 08, 2026

Glaukos sets April 29 earnings release, webcast after market close - Stock Titan

Apr 08, 2026

Apr 07, 2026

Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $135 - Moomoo

Apr 07, 2026

A Look At Glaukos (GKOS) Valuation As Epioxa Showcased At ASCRS Annual Meeting - simplywall.st

Apr 07, 2026

Glaukos Stock 5-Day Winning Spree: Stock Climbs 13% - Trefis

Apr 07, 2026

Apr 06, 2026

Does Glaukos (GKOS) Using Epioxa at ASCRS Hint at a Broader Corneal-Health Strategy Shift? - Yahoo Finance

Apr 06, 2026

Glaukos to Present Multiple Scientific Abstracts at ASCRS Annual Meeting - National Today

Apr 06, 2026

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refrac - PharmiWeb.com

Apr 06, 2026

Glaukos brings Epioxa symposium and 9 eye-care studies to ASCRS - Stock Titan

Apr 06, 2026

Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS - MarketBeat

Apr 06, 2026

Apr 04, 2026

Q4 2024 Glaukos Corp Earnings Call Transcript - GuruFocus

Apr 04, 2026

Apr 03, 2026

Glaukos (NYSE: GKOS) CDO reports RSU tax withholding transactions - Stock Titan

Apr 03, 2026

Glaukos (NYSE: GKOS) CFO withholds 1,589 shares for RSU tax obligations - Stock Titan

Apr 03, 2026

Glaukos (GKOS) president uses 3,169 shares to cover tax withholding - Stock Titan

Apr 03, 2026

Glaukos (GKOS) CEO gifts 180,308 shares to family trust - Stock Titan

Apr 03, 2026

Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo

Apr 03, 2026

Cash per share of Glaukos Corp – DUS:6GJ - TradingView

Apr 03, 2026

Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules - ChartMill

Apr 03, 2026